NICE end-of-life drug extension.
|Article Type:||Brief article|
Terminal care (Reports)
Trade and professional associations (Services)
|Publication:||Name: Community Practitioner Publisher: Ten Alps Publishing Audience: Academic Format: Magazine/Journal Subject: Health; Health care industry Copyright: COPYRIGHT 2009 Ten Alps Publishing ISSN: 1462-2815|
|Issue:||Date: Feb, 2009 Source Volume: 82 Source Issue: 2|
|Topic:||Event Code: 360 Services information|
|Product:||Product Code: 8620000 Professional Membership Assns NAICS Code: 81392 Professional Organizations SIC Code: 8621 Professional organizations|
|Geographic:||Geographic Scope: United Kingdom Geographic Code: 4EUUK United Kingdom|
The National Institute for Health and Clinical Excellence (NICE) is
extending the threshold at which end-of-life drugs are considered to be
Unite/CPHVA professional officer Ros Godson stated: 'This is the best outcome for this situation. However, deciding upon treatment by cost goes against many morals. Sadly, it is a reality within a cash-limited health system.'
Patients who could have access to these drugs include those whose life expectancy is 24 months or less, and where there is evidence the drug will extend life by three months or more, no alternative treatment with comparable benefits, or treatment is licensed for a small patient population.
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|